{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:39:27Z","timestamp":1769078367035,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p><jats:bold>Aim:\u2002<\/jats:bold>Amisulpride at low dosages enhances dopaminergic neurotransmission by preferentially blocking presynaptic D2\/D3 receptors. Thus, low dosages of amisulpride are expected not to increase prolactin levels. The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold>Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300\u2003mg of amisulpride per day.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>The mean dosage of amisulpride was 195.0\u2003\u00b1\u200351.0\u2003mg\/day, and serum level of prolactin was 76.1\u2003\u00b1\u200343.4\u2003ng\/mL. The prolactin level was significantly higher in women (110.7\u2003\u00b1\u200349.3\u2003ng\/mL) than in men (53.1\u2003\u00b1\u200315.9\u2003ng\/mL) after administering amisulpride (<jats:italic>P<\/jats:italic>\u2003=\u20030.021), while the dosage of amisulpride did not differ significantly between men (200.0\u2003\u00b1\u200342.6\u2003mg\/day) and women (187.5\u2003\u00b1\u200364.1\u2003mg\/day) (<jats:italic>P<\/jats:italic>\u2003=\u20030.576).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold>The low dosages of amisulpride elevate serum prolactin level in the majority of patients. This finding indicates that the dose\u2010reduction of amisulpride has little effect to relieve amisulpride\u2010induced hyperprolactinemia at therapeutic dosages. Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2011.02296.x","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T05:24:24Z","timestamp":1326864264000},"page":"69-73","source":"Crossref","is-referenced-by-count":12,"title":["Hyperprolactinemia induced by low\u2010dosage amisulpride in Korean psychiatric patients"],"prefix":"10.1111","volume":"66","author":[{"given":"Bun\u2010Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung\u2010Gul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae\u2010Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heon\u2010Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho\u2010Kyoung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young\u2010Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31815ac4e5"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818ba5d8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker H","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.2.180"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199705002-00006"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","article-title":"Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group","volume":"156","author":"Danion JM","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245616"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_2_6_10_2","first-page":"102","article-title":"Resolution of amisulpride\u2010associated amenorrhea by switching to aripiprazole","volume":"3","author":"Lee BH","year":"2006","journal-title":"Psychiatry Invest."},{"key":"e_1_2_6_11_2","first-page":"419","article-title":"Hyperprolactinemia after low dose of amisulpride","volume":"25","author":"Kopecek M","year":"2004","journal-title":"Neuro Endocrinol. Lett."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.02.001"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.07.006"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.39761"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(96)00100-1"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035303"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1826-6"},{"key":"e_1_2_6_18_2","first-page":"575","article-title":"Diagnosis and management of hyperprolactinemia","volume":"169","author":"Serri O","year":"2003","journal-title":"CMAJ"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0168"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/09513591003632233"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.11.037"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00011"},{"key":"e_1_2_6_23_2","volume-title":"Practice Guidelines for the Treatment of Patients with Schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00897.x"},{"key":"e_1_2_6_25_2","first-page":"143","article-title":"Antipsychotic\u2010induced hyperprolactinemia and sexual dysfunction","volume":"36","author":"Compton MT","year":"2002","journal-title":"Psychopharmacol. Bull."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107086516"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2011.02296.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2011.02296.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T22:44:01Z","timestamp":1742337841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2011.02296.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1440-1819.2011.02296.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2011.02296.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}